<DOC>
	<DOC>NCT00923702</DOC>
	<brief_summary>The primary study hypothesis is that a two-dose human papillomavirus (HPV) vaccine regimen would offer similar immunogenicity and protection as that of a three-dose regimen to girls against persistent HPV infection and cervical neoplasia caused by HPV types included in the vaccine.</brief_summary>
	<brief_title>Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Apparently healthy, ambulant girls aged 10 18 years Unmarried girls Girls with intact uterus Resident in the villages chosen for the study Girls with any severe and/or debilitating illness Past history of allergy to any medication</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>